Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

Amid the questions about the Yeztugo rollout, Gilead’s second quarter performance offered some reassurance about the ...

Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year ...

(Nasdaq: GILD) announced today its second quarter 2025 results of operations. "This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world’s first ...

Gilead Sciences ( NASDAQ: GILD) was upgraded to Buy from Hold at Truist after the company raised full year sales and profit ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q2 CY2025 results topping the market’s revenue expectations, ...

With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to ...

Despite decades of medical progress, HIV continues to devastate Black communities. The statistics are sobering. The ...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD) and its peers. Over the next few years, ...